| Aaron B Jones, MD | |
|
401 W Poplar St, Emergency Department, Walla Walla, WA 99362-2846 | |
| (509) 525-3320 | |
| Not Available |
| Full Name | Aaron B Jones |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 23 Years |
| Location | 401 W Poplar St, Walla Walla, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265446678 | NPI | - | NPPES |
| 8395170 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 43233 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence St Mary Medical Center | Walla walla, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Providence Health And Services - Washington | 2860552973 | 217 |
News Archive
Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, and Yale University today announced the discovery by Thomas Steitz, Ph.D., co-founder of Rib-X and Yale University professor, of important new ribosomal structures of antibiotics, enabling the potential creation of novel treatments for drug resistant infections, including resistant tuberculosis (TB).
Astellas reported today that the efficacy and safety data of the isavuconazole invasive aspergillosis study (SECURE) were presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain.
Researchers from Singapore conducted a study to assess the spike protein-specific humoral and cellular immunity in Ad26.COV2.S vaccinated individuals either primed with Ad26.COV2.S only, or boosted with a homologous or heterologous second dose.
Northwestern Medicine is the first site open for enrollment in a national clinical research trial of a human embryonic stem cell-based therapy for participants with a subacute thoracic spinal cord injury. Following the procedure, participants will receive rehabilitation treatment at The Rehabilitation Institute of Chicago (RIC).
› Verified 9 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Northwest |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184786527 PECOS PAC ID: 5799688230 Enrollment ID: O20040220000099 |
News Archive
Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, and Yale University today announced the discovery by Thomas Steitz, Ph.D., co-founder of Rib-X and Yale University professor, of important new ribosomal structures of antibiotics, enabling the potential creation of novel treatments for drug resistant infections, including resistant tuberculosis (TB).
Astellas reported today that the efficacy and safety data of the isavuconazole invasive aspergillosis study (SECURE) were presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain.
Researchers from Singapore conducted a study to assess the spike protein-specific humoral and cellular immunity in Ad26.COV2.S vaccinated individuals either primed with Ad26.COV2.S only, or boosted with a homologous or heterologous second dose.
Northwestern Medicine is the first site open for enrollment in a national clinical research trial of a human embryonic stem cell-based therapy for participants with a subacute thoracic spinal cord injury. Following the procedure, participants will receive rehabilitation treatment at The Rehabilitation Institute of Chicago (RIC).
› Verified 9 days ago
| Entity Name | Providence Health & Services - Washington |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922259738 PECOS PAC ID: 2860552973 Enrollment ID: O20081223000478 |
News Archive
Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, and Yale University today announced the discovery by Thomas Steitz, Ph.D., co-founder of Rib-X and Yale University professor, of important new ribosomal structures of antibiotics, enabling the potential creation of novel treatments for drug resistant infections, including resistant tuberculosis (TB).
Astellas reported today that the efficacy and safety data of the isavuconazole invasive aspergillosis study (SECURE) were presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain.
Researchers from Singapore conducted a study to assess the spike protein-specific humoral and cellular immunity in Ad26.COV2.S vaccinated individuals either primed with Ad26.COV2.S only, or boosted with a homologous or heterologous second dose.
Northwestern Medicine is the first site open for enrollment in a national clinical research trial of a human embryonic stem cell-based therapy for participants with a subacute thoracic spinal cord injury. Following the procedure, participants will receive rehabilitation treatment at The Rehabilitation Institute of Chicago (RIC).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Aaron B Jones, MD 401 W Poplar St, Emergency Department, Walla Walla, WA 99362-2846 Ph: () - | Aaron B Jones, MD 401 W Poplar St, Emergency Department, Walla Walla, WA 99362-2846 Ph: (509) 525-3320 |
News Archive
Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, and Yale University today announced the discovery by Thomas Steitz, Ph.D., co-founder of Rib-X and Yale University professor, of important new ribosomal structures of antibiotics, enabling the potential creation of novel treatments for drug resistant infections, including resistant tuberculosis (TB).
Astellas reported today that the efficacy and safety data of the isavuconazole invasive aspergillosis study (SECURE) were presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain.
Researchers from Singapore conducted a study to assess the spike protein-specific humoral and cellular immunity in Ad26.COV2.S vaccinated individuals either primed with Ad26.COV2.S only, or boosted with a homologous or heterologous second dose.
Northwestern Medicine is the first site open for enrollment in a national clinical research trial of a human embryonic stem cell-based therapy for participants with a subacute thoracic spinal cord injury. Following the procedure, participants will receive rehabilitation treatment at The Rehabilitation Institute of Chicago (RIC).
› Verified 9 days ago
Dr. Philip A Green, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 401 W Poplar St, Psmmc Er, Walla Walla, WA 99362 Phone: 509-522-5802 Fax: 509-522-5541 | |
Shirley Robin Vonhaven, DO Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 401 W Poplar, Walla Walla, WA 99362 Phone: 509-522-5802 Fax: 509-522-5950 | |
Jared L Wutzke, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 401 W Poplar St, Psmmc Er, Walla Walla, WA 99362 Phone: 509-522-5802 Fax: 509-522-5541 | |
Dr. Morgan C Galante, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1111 S 2nd Ave, Walla Walla, WA 99362 Phone: 509-897-3700 | |
Joilo Barbosa, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 123 E Main St # 268, Walla Walla, WA 99362 Phone: 509-529-2966 | |
Eric Trent Brown, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 401 W Poplar St, Psmmc Er, Walla Walla, WA 99362 Phone: 509-522-5802 Fax: 509-522-5541 |